Communiqués de presse

InnaVirVax lands $4.9 Million in Series B funding Round

This second round of funding was lead by the Pradeyrol Development family office along with the private equity fund Fa Dièse, the FRCI, and the historical investors managed by CapDecisif Management. This capital increase will allow InnaVirVax to conduct the Phase I/IIa clinical trial of the VAC-3S immunotherapy in HIV-1 infected patients.

[+] Previous page

  • Print
  • Envoyer
Plan d’accès->en Dowload available documents